Curis, Inc.

Good afternoon, ladies and gentlemen, and welcome to the Curious First Quarter 2026 Business Update Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press zero for the operator. This call is being recorded on Tuesday, May 12, 2026. I would now like to turn the conference over to Diane Fedruval, Chief Financial Officer. Please go ahead.

Thank you, and welcome to the QRIS first quarter 2026 business update call. Before we begin, I'd like to encourage everyone to go to the investor section of our website at www.qris.com to find our first quarter 2026 business update press release and related financial tables. I would also like to remind everyone that during the call, we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. For additional details, please see our SEC filings. Joining me today on today's call are Jim Dentzer, President and Chief Executive Officer, Dr. Jonathan Zung, Chief Development Officer, and Dr. Ahmed Hamdi, Chief Medical Officer. We will also be available for a question and answer period at the end of the call. I'd now like to turn the call over to Jim.

Thank you, Diana. Good afternoon, everyone, and welcome to our first quarter business update call. We continue to make steady progress in our taking lymphoma study in primary CNS lymphoma, one of the most rare and most difficult to treat of the NHL subtypes. As a reminder... The take-in lymphoma study is a single-arm registrational study with an ORR endpoint that is evaluating M of assertive in combination with ibrutinib after a patient has progressed on BTKI therapy. And after collaborative discussions with both FDA and EMA, we expect the study to support accelerated submissions in both the U.S. and Europe. We anticipate providing updated M of assertive clinical data from the taking lymphoma combination study with ibrutinib in patients with relapsed refractory PCNSL in the first half of 2027. We continue to make good progress on enrollment on this registrational study and appreciate the ongoing support of our clinical investigators, key opinion leaders, and regulatory authorities. As you recall, last year we engaged with a number of key opinion leaders who were excited and highly supportive about expanding our MOV assertive studies into additional NHL subtypes. They were especially interested in exploring MOV assertive's potential to fundamentally change the treatment paradigm for CLL patients, where the current standard of care is BTK inhibitors. Over the last decade, BTK inhibitors have become standard of care in CLL and NHL because of their ability to help patients achieve objective responses. However, these responses are typically partial responses, not complete remission. The result is that patients treated with a BTK inhibitor end up having to stay on it in chronic treatment for the rest of their lives. Additionally, because they never achieve complete remission, many of these patients develop BTKI-resistant mutations, and ultimately their disease progresses. We're looking to improve upon the current standard of care by adding emavucirtib to a patient's BTKI regimen, applying a dual blockade to the two biologic pathways driving CLL. This dual blockade can enable patients whose NHL subtype partially responds to a VTK inhibitor to achieve deeper responses with the combination, including the ability to achieve complete remission or undetectable disease and the potential for time-limited treatment. If we are successful adding emavisertib to BTKI could change the treatment paradigm in CLL, reducing the risk of developing a treatment-resisting mutation and improving a patient's overall quality of life. The first step in testing this hypothesis in CLL is our proof-of-concept study in patients currently on BTKI monotherapy who have achieved partial remission but have been unable to achieve complete remission or undetectable MRD. We anticipate the dosing of the initial five patients in the TAKE-AIM CLL combination study with Zanabrutinib by mid-2026, and we expect to have initial data in December. In January, one of our collaborators, Dr. Patrick Grierson of the Siteman Cancer Center, at Washington University in St. Louis, presented a poster with initial clinical data in gastric and esophageal cancer at the ASCO GI Cancers Symposium. In this study, patients are treated with M of assertive in combination with FOLFOX and anti-PD-1 plus or minus receptin as first-line therapy for metastatic or unresectable gastroesophageal cancers. The initial data showed results for 16 valuable patients, demonstrating both a manageable toxicity profile and encouraging preliminary results. As you can see, we had a very productive quarter and look forward to an exciting 2026 as we advance our registrational study in PCNSL and our proof-of-concept study in CLL. With that, I'll turn the call back over to DeAntha for the financial update. DeAntha?